Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1999 Aug;22(8 Suppl):IV37-43.
doi: 10.1002/clc.4960221607.

Combination therapy for acute myocardial infarction: glycoprotein IIb/IIIa inhibitors plus thrombolysis

C P Cannon  1
Affiliations
Review

Combination therapy for acute myocardial infarction: glycoprotein IIb/IIIa inhibitors plus thrombolysis

C P Cannon. Clin Cardiol. 1999 Aug.

Abstract

Although thrombolytic therapy has been a major advance in the treatment of acute ST-segment elevation myocardial infarction (MI), new thrombolytic agents have been unable to improve early reperfusion. Because aspirin has been shown to be a very effective adjunctive agent in patients with acute MI, it has been hypothesized that the use of platelet glycoprotein (GP) IIb/IIIa receptor inhibitors combined with thrombolytic agents would lead to more effective platelet inhibition and improved angiographic and clinical efficacy. Emerging experimental and clinical data, including the Thrombolysis in Myocardial Infarction (TIMI)-14 trial, suggest that combining GP IIb/IIIa receptor inhibition with reduced-dose thrombolytic therapy improves early infarct-related artery patency without increasing bleeding risk. Thus, given the strong clinical and physiologic rationale, clinical investigation in patients with acute ST-segment elevation MI is currently focused on combining GP IIb/IIIa receptor inhibitors with reduced-dose fibrinolytic agents in acute MI.

PubMed Disclaimer

References

    1. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI) : Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397–402 - PubMed
    1. iSIS‐2 (Second International Study of Infarct Survival) Collaborative Group : Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS‐2. Lancet 1988; 2: 349–360 - PubMed
    1. Cannon CP, Braunwald E: GUSTO, TIMI and the case for rapid reperfusion. Acta Cardiol 1994; 49: 1–8 - PubMed
    1. The GUSTO Angiographic Investigators : The effects of tissue plasminogen activator, streptokinase, or both on coronary‐artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615–1622 - PubMed
    1. Ito H, Tomooka T, Sakai N, Yu H, Higashino Y, Fujii K, Masuyama T, Kitabatake A: Lack of myocardial perfusion immediately after successful thrombolysis: A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992; 85: 1699–1705 - PubMed

MeSH terms

Substances